Search details
1.
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.
Int J Cancer
; 151(9): 1542-1554, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-35737508
2.
HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance.
Clin Cancer Res
; 29(15): 2894-2907, 2023 Aug 01.
Article
in English
| MEDLINE | ID: mdl-37199727
3.
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variants.
Pigment Cell Melanoma Res
; 35(6): 573-586, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35912549
4.
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival.
Cancers (Basel)
; 14(9)2022 Apr 22.
Article
in English
| MEDLINE | ID: mdl-35565222
5.
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Eur J Cancer
; 161: 99-107, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34936949
6.
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions.
Cancers (Basel)
; 14(17)2022 Aug 23.
Article
in English
| MEDLINE | ID: mdl-36077603
7.
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology.
Eur J Cancer
; 148: 340-347, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33773277
8.
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Eur J Cancer
; 159: 113-124, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34742158
Results
1 -
8
de 8
1
Next >
>>